Maxcyte, INC 10-Q quarterly reports

MaxCyte reports a 7% year-over-year revenue decrease for Q1 2026, driven by lower core revenue, though SPL milestones and royalties saw a significant increase.

MaxCyte, Inc. reported a significant increase in net loss and a decrease in total revenue for the third quarter and first nine months of 2025, alongside a major workforce reduction and CFO transition.

MaxCyte, Inc. reported an 18% decline in total revenue for Q2 2025, primarily due to a significant decrease in non-core program-related revenue, despite an 8% increase in core revenue.

MaxCyte's Q1 2025 results show a slight revenue decrease and a net loss, but the company highlights the acquisition of SeQure Dx and a new SPL agreement.

MaxCyte's third quarter results show a 17% increase in revenue year-over-year, driven by disposables and program-related revenue, while the company continues to invest in growth and development.

MaxCyte's second quarter 2024 results show a revenue increase driven by strategic platform licenses, despite a decrease in core revenue.

MaxCyte's first quarter 2024 results show a 32% increase in revenue compared to the same period last year, primarily driven by growth in strategic platform licenses and core business revenue.